In chronic kidney disease, at what hemoglobin level should erythropoietin therapy be started and when should iron supplementation be initiated?

Erythropoietin and Iron Therapy in CKD

For adult CKD patients not on dialysis (CKD ND), initiate ESA therapy when hemoglobin falls below 10.0 g/dL, individualizing based on rate of decline and symptoms; for dialysis patients (CKD 5D), start ESA when hemoglobin is between 9.0-10.0 g/dL to prevent falling below 9.0 g/dL. 1

ESA Initiation Thresholds

Non-Dialysis CKD Patients

• Do not initiate ESA if Hb ≥10.0 g/dL 1
• Consider ESA when Hb <10.0 g/dL, factoring in:
  • Rate of hemoglobin decline
  • Prior response to iron therapy
  • Transfusion risk
  • Presence of anemia symptoms 1

Dialysis Patients (CKD 5D)

• Start ESA when Hb is 9.0-10.0 g/dL to prevent dropping below 9.0 g/dL 1
• This represents a more proactive approach for dialysis patients compared to non-dialysis patients

Target Hemoglobin During Maintenance

• Do not maintain Hb above 11.5 g/dL in adults (Grade 2C) 1
• Never intentionally increase Hb above 13.0 g/dL (Grade 1A) 1
• The evidence strongly supports avoiding higher targets due to increased cardiovascular risks, stroke, and vascular access complications

Iron Supplementation Timing

Before Starting ESA

Address iron deficiency first - correct all causes of anemia including iron deficiency before initiating ESA therapy 1

For Patients NOT on ESA or Iron

Initiate iron therapy (IV preferred, or oral for CKD ND) when: 1

• TSAT ≤30% AND
• Ferritin ≤500 ng/mL

This applies when you want to increase hemoglobin without starting ESA, based on symptoms and clinical goals

For Patients Already on ESA

Add iron supplementation when: 1

• TSAT ≤30% AND
• Ferritin ≤500 ng/mL
• Goal is to increase Hb or decrease ESA dose requirements

Pediatric Patients

Different thresholds apply:

• Not on ESA: Give iron when TSAT ≤20% and ferritin ≤100 ng/mL 1
• On ESA: Maintain TSAT >20% and ferritin >100 ng/mL 1

Route of Iron Administration

For CKD ND patients: Choose between IV or oral iron based on:

• Severity of iron deficiency
• Venous access availability
• Prior response to oral iron
• Side effect history
• Patient compliance 1

For hemodialysis patients: IV iron is generally preferred due to better absorption and ongoing losses

Monitoring Requirements

Iron Status

• Check TSAT and ferritin at least every 3 months during ESA therapy 1
• Test more frequently when:
  • Initiating or increasing ESA dose
  • Blood loss occurs
  • Monitoring response to IV iron course
  • Circumstances suggesting iron depletion 1

Hemoglobin Monitoring

• CKD 3: At least annually 1
• CKD 4-5 ND: At least twice yearly 1
• CKD 5HD and 5PD: At least every 3 months 1
• During ESA maintenance (CKD ND): At least every 3 months 1

Critical Safety Considerations

Use ESA with extreme caution or avoid entirely in patients with: 1

• Active malignancy (especially when cure is anticipated) - Grade 1B
• History of stroke - Grade 1B
• History of malignancy - Grade 2C

Balance risks versus benefits including stroke, vascular access loss, hypertension, and cardiovascular events against reducing transfusions and anemia symptoms 1

The KDIGO 2012 guidelines remain the authoritative source, emphasizing individualized therapy within these evidence-based parameters while prioritizing patient safety over aggressive hemoglobin targets.